Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Non Operating Income of $5.9 million for Q4 2025, up 9243.26% on a QoQ basis from $62984.0 in Q3 2025, and up 16437.48% year-over-year from N/an in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Non Operating Income history runs 2 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- Quarterly Non Operating Income rose 16437.48% year-over-year to $5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 5245.07% YoY) and the FY2025 annual result came in at $5.9 million, up 5245.07% from the prior year.
- Non Operating Income was $5.9 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $62984.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $5.9 million in Q4 2025 and bottomed at -$38029.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 5.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 62,984.00 |
| Jun 30, 2025 | 1,711.00 |
| Mar 31, 2025 | -38,029.00 |
| Dec 31, 2024 | -36,020.00 |
| Sep 30, 2024 | -32,522.00 |
| Jun 30, 2024 | -21,606.00 |
| Mar 31, 2024 | -24,747.00 |